Drugs / CRN01941
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03936166 | Apr → Dec 2019 | — | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-04-06 | Crinetics Pharmaceuticals Inc. | Results Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update crinetics.com ↗
Phase 1 data for CRN01941 in healthy volunteers showed that the compound did not represent an improvement over paltusotine. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-06 | Crinetics Pharmaceuticals Inc. | Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update crinetics.com ↗ |
| 2019-05-21 | Crinetics Pharmaceuticals Inc. | Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors crinetics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRN01941 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936166 ↗ |
| Route | Oral | “CRN01941 Oral Solution” NCT03936166 ↗ |